Press Releases

Diazon Pharmaceutical’s anti-cancer agent DZ-2384 mechanism for high activity and low neurotoxicity published by McGill researchers in Science Translational Medicine

Montreal, QC, November 16th 2016 – Diazon Pharmaceuticals Inc. today announced the publication of a preclinical oncology study identifying the novel mechanism of action of its new synthetic diazonamide compound, DZ-2384, in Science Translational Medicine. The results show that a distinct mode of binding to a classic therapeutic site in tubulin translates into superior anti-tumor activity and safety, including lack of neurotoxicity, with pre-clinical proof of concept in a wide range of cancers including triplenegative breast cancer and pancreatic cancer.